Johnson & Johnson ranks near the peer group median, with stability as the main structural strength, while growth is less supportive than the other dimensions.
Peer-relative scores, weakest to strongest
Johnson & Johnson is a global healthcare conglomerate operating across pharmaceuticals, medical devices, and consumer health. The company is known for its diversified product portfolio and longstanding presence in regulated markets.
Capital efficiency and profitability—evidenced by a ROIC of 24.91% and an operating margin of 26.7%—position Johnson & Johnson for a valuation premium. Yet, the company continues to trade at a notable discount, with its forward P/E of 18.4x well below the peer median of 25.1x. The main issue is the market’s reluctance to fully reward JNJ’s earnings and capital returns, even as revenue growth accelerates.
Net income of €26.8bn confirms the company’s earnings power, and recent revenue growth of +9.9% year-over-year outpaces most direct competitors. This performance has prompted multiple analyst upgrades and higher price targets in April 2026, a positive signal, but the valuation gap persists. The analyst optimism is noted, but strong fundamentals are not yet translating into a rerating, as the market waits for sustained growth to become the norm rather than a quarterly occurrence.
Recent external developments partly offset the discount narrative. The introduction of products such as ICOTYDE and TECVAYLI plus DARZALEX FASPRO, alongside raised full-year guidance and robust Q1 revenue growth, support the execution story and reinforce JNJ’s competitive positioning. However, while these factors have improved sentiment and market confidence, they have not yet closed the valuation gap—investors appear to be waiting for a longer track record of above-peer growth and continued product momentum before reassessing the discount.
Compared to peers, Johnson & Johnson stands at the top end for profitability and capital efficiency, with most rivals either lagging in growth or trading at higher multiples. The discount is more severe than many peers with similar quality profiles, and appears partly driven by factors specific to JNJ—such as its recent growth volatility and market skepticism about the sustainability of its innovation pipeline.
A more constructive read would require JNJ to sustain its above-peer growth trajectory for several quarters and demonstrate that product innovation consistently translates into market share gains. Supporting improvement would include a stable regulatory environment for new launches. Until then, Johnson & Johnson appears as a discount despite strong fundamentals.
Break down JNJ's position across all dimensions with the full interactive tool.
This analysis is rule-based and descriptive. Peer-relative scores are derived from functional peer group comparisons using publicly available financial data. Scores reflect structural positioning only and do not constitute investment advice, a buy or sell recommendation, or a forecast of future performance. AssetNext peer scores are recalculated periodically as new data becomes available.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Because scores are peer-relative, the same company can have slightly different scores in different index universes. On comparison pages, both companies are shown within their shared peer universe wherever possible — so the scores are directly comparable. The peer basis is stated on each score card.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.